Fri, Aug 29, 2014, 1:44 PM EDT - U.S. Markets close in 2 hrs 16 mins

Recent

% | $
Quotes you view appear here for quick access.

Arena Pharmaceuticals, Inc. Message Board

  • sauve9 sauve9 Dec 2, 2013 12:33 PM Flag

    Ruminations with no substantiation

    65M shares short positions are 90% held by 6 or 7 related hedge funds sharing information.
    A singular large entity is accumulating Arena shares at a fast clip, will hit 10% in a week or 2.
    Vivus will retain counsel for sale of company in February, asking $1B, no takers.
    Arena will acquire a private biotech in February, price less than 100M.
    Eisai plans Zonisamide as a weight-loss agent.

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Could be that a certain person we know of that is consulting with weight loss companies and with Eisai is helping in the DD???

    • Zafgen!

    • oh yeah... and 65M shorted shares by non-disclosure hedgies are counting more on an overall market drop than anything to do with ARNA....... SHORT DEAD MONEY WITH UPSIDE RISK.

      • 2 Replies to diogenes_320bc
      • ...and do not forget Diogenes, that the upside risk is UNLIMITED on the short side, and also a lot of short sellers forget that sometimes, but especially in the case of Arena, there can be "due bills" EVEN AFTER closing the position and taking their big losses.
        Most retail shorts do not even bother to find out where their shorts were borrowed from and too bad for them. Wasn't a problem back in the 70's when everything was done inside our borders but today, LOOK OUT!
        You don't wanna get a due bill from the Chinese or some Latvian Mobsters, and thing is THEY GOT THE LAW BEHIND THEM!
        and don't go crying to the SEC, it is out of their jurisdiction and they hate retail shorts anyway.
        You short Arena?
        Most good ol' American borrowed shares are locked up and paying interest by hedge funds.
        There hasn't been clean Amreican Arena shares to borrow for months now.
        Your discount broker probably borrowed your Arena shares from Latvia, I would not be surprised shorty, because they are free over there.
        Until you get the due bill Yikes!

        Sentiment: Strong Buy

      • The definiton of risk to most non-professionals is risk of loss of capital. Making the words "UPSIDE RISK" oxymoron.

    • Zonisamide may be good for non-responders to Belviq, Eisai could then cover the whole market. More arrows in the quiver. it has side effects that may make it less desirable than Belviq, similar to what you may see with the stuff from vvus.
      here is a list of side effects from Z : Zonisamide was tolerated well in this study. Premature withdrawals were much less frequent than expected in obesity trials of similar duration. Only 1 patient withdrew from the zonisamide group citing an adverse effect. Overall, fatigue was the only adverse effect that occurred at a significantly higher frequency for zonisamide treatment than for placebo. Our data collection relied on spontaneous reporting and open-ended inquiries that may have yielded a lower frequency of adverse effects than could be elicited with structured questionnaires. Although not observed frequently in this study, the following adverse effects occurred frequently with zonisamide therapy in epilepsy trials: dizziness, cognitive impairment, and somnolence.8,13 Because zonisamide is a sulfonamide, there is a potential for hypersensitivity reactions. Although rare, kidney stones and serious hematologic events have been reported with zonisamide therapy in patients with epilepsy. Consistent with data from epilepsy trials, we noted an increase in serum creatinine concentration with zonisamide therapy, but not with placebo. Whereas the increase in the first 16 weeks (approximately 16%) was significant, there was no further increase in the extension phase; no value exceeded the upper limit of normal range, and there were no clinical events associated with the increase.

      Sentiment: Strong Buy

    • S9,

      Ref. "Eisai plans Zonisamide as a weight-loss agent."

      I really don't get it... Please clarify, here are some references I just looked up.

      From Page 1
      =============
      NDA 020789/S-012
      FDA Approved Labeling Text dated 1/24/2012
      ZONEGRAN® (zonisamide) capsules
      =============

      From Page 21
      =============
      DOSAGE AND ADMINISTRATION
      ZONEGRAN (zonisamide) is recommended as adjunctive therapy for the treatment of partial seizures in adults....
      =============

      Page 18
      =============
      METABOLIC AND NUTRITIONAL - Weight Loss
      ZONEGRAN (n=269) = 3%
      PLACEBO (n=230) = 2 %
      =============

      I am not sure how a drug that is FDA approved for "partial seizures" with 1% over a Very Weak 2% Placebo could be a competition against a Weight Loss Drug as Belviq that showed or I should say is currently showing numbers over 10% with most of the current patients taking B . Personally, I am closing at 16% Weight Loss after a little over 5 Months taking B.

      Please expand on your statement, if possible... Thanks...

    • stop with the nonsense

    • Ruminations with no substantiation
      65M shares short positions are 90% held by 6 or 7 related hedge funds sharing information. Possible.
      A singular large entity is accumulating Arena shares at a fast clip, will hit 10% in a week or 2.Possible
      Vivus will retain counsel for sale of company in February, asking $1B, no takers. No way.
      Arena will acquire a private biotech in February, price less than 100M. No way.
      Eisai plans Zonisamide as a weight-loss agent. Ask Dr Daniel for his opinion on this.

      Sentiment: Strong Buy

    • . . . Zonisamide might be an excellent addition to help belv's performance . . . OREX's Epatic weight-loss drug already employs it . . . "In a Phase 2b clinical trial of Empatic 360 mg, patients completing 24 weeks of therapy, lost 9.9% of their baseline body weight" . . .

      • 1 Reply to neo17a
      • Eisai owns all rights to Zonisamide for obesity. They won that right in a lawsuit with Orexigen. Eisai has an open clinical trial for Zonisamide for obesity. Eisai has close to worldwide rights to Belviq for the treatment of obesity. Make no mistake, Eisai is planning with regards to Zonisamide for obesity.
        Much as my fellow longs like to ignore it, there are strong, very strong, signals that Eisai intends to do something in the obesity field with Zonisamide.

        Sentiment: Strong Buy

    • These are fun, S9, especially for longs.

 
ARNA
4.17+0.05(+1.21%)1:44 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.